The Unwitnessed Debt
The lobby of Sterling Biotech rose forty feet into a ceiling of smoked glass and cantilevered steel, designed to make every visitor feel insignificant. Adrian Ashby felt the weight of that architecture every morning as he swiped his degraded ID badge through the turnstile, the same badge that had once granted him access to the executive labs on the fourteenth floor but now only opened the basement archive room and the员工 cafeteria on sub-level two.
Three years ago, he had stood at a podium in this same building, presenting his research on CRISPR-based epigenetic correction to an audience that included three Nobel laureates and Grant Sterling himself. The old man had smiled from the front row, nodding along as Adrian explained his breakthrough in targeted gene silencing. Two months later, Adrian had been reassigned to data entry. Six months after that, he had discovered why: his name had been removed from the pending patent applications, replaced by Jasper Sterling’s.
The turnstile chirped its acceptance. Adrian walked through.
The lobby’s digital clock read 6:47 PM, well past the standard research staff’s departure time, but the archive room didn’t operate on standard hours. It operated on the principle that someone needed to be there to process the endless river of data generated by the Sterling machine, and that someone had proven he could be exploited indefinitely because he had nowhere else to go.
The basement hallway stretched ahead, fluorescent lights humming at a frequency that sat just below pain. Adrian’s footsteps echoed against concrete walls painted institutional beige. He passed the server room, the cold storage unit, and finally reached the archive door—plain steel, no window, a keypad that required a six-digit code he changed weekly because Sterling security protocols were paranoid even about their data entry grunts.
He typed 7-4-2-9-1-8. The lock clicked open.
Inside, the room was a cathedral of dead science. Twenty rows of floor-to-ceiling shelving units held boxes of physical records—the paper backups that Grant Sterling insisted on maintaining despite the company’s advanced digital infrastructure. “Data can be hacked,” the old man had said once, in a rare moment of candor during Adrian’s orientation three years ago. “Paper can only be burned.”
Adrian had never understood why Grant would share that observation with a low-level hire. He understood now. The old man had been testing him, even then, seeing if he would ask the wrong questions.
He settled into his workstation—a metal desk at the far end of the room, dominated by a terminal that ran software from the previous decade. His task for the evening was straightforward: cross-reference batch numbers from a 2019 clinical trial against patient consent forms stored in boxes 447 through 512. It was the kind of work that would take a competent database administrator approximately four minutes. Adrian had been told it would take him three weeks.
He opened box 447. Inside, manila folders were arranged alphabetically by patient surname. He pulled the first one: ABBOTT, JAMES. The consent form was standard Sterling Biotech boilerplate, signed in blue ink, dated September 2019. Genetic testing for rare disease markers. Nothing unusual.
He pulled the second folder. ALDERMAN, SARAH. Same form, same signature block, same date.
The third folder was empty.
Adrian frowned. He checked the folder tab: ANDERS, MICHAEL. The interior was clean, no paper residue, no indication that a document had ever been inserted. He set it aside and pulled the fourth folder. ASHBY, ADRIAN.
His own name stared back at him.
He opened the folder. Inside, there was a single sheet of paper—not a consent form, but a memorandum on Sterling Biotech letterhead, dated November 2019.
*Subject: Ashby, Adrian — Genetic Profile Capture*
*Method: Residual DNA collected from coffee cup, break room, 10/14/2019*
*Status: Complete. Full sequence captured, uploaded to Project Chimera server.*
He read it three times. Coffee cup. They had taken his DNA from a coffee cup, three months before he had been reassigned to data entry. They had sequenced his genome without his knowledge, without his consent, and they had uploaded it to something called Project Chimera.
Project Chimera.
The name triggered a cascade of memory fragments. Late nights in the Harvard genetics lab, eight years ago, when he had been a postdoctoral fellow working under Grant Sterling’s supervision. Grant had mentioned the project once, in passing, during a discussion about germline editing. “Chimera is the future,” he had said, “but the ethics boards aren’t ready for it.” Adrian had assumed it was theoretical. A thought experiment. A way to push the boundaries of what was scientifically possible without actually doing it.
He had been wrong.
His hands moved before his mind caught up, pulling boxes at random, spreading their contents across the metal desk. He found his own file again, tucked into a box labeled “MISCELLANEOUS — 2019” that should not have contained personnel records. He found a second memorandum, dated December 2019, that referenced a second sample collection: “Residual DNA collected from lab coat, locker 14-B.” They had taken his DNA twice.
He found Nadia Ashford’s file in box 489.
The name stopped him cold. Nadia Ashford. The woman he had met at a conference eight years ago, shared exactly one night with, and never seen again—until six months ago, when he had spotted her in the Sterling Biotech parking lot, picking up her son from a school bus that stopped at the facility’s employee daycare center.
Her son. Toby. Eight years old. Born approximately nine months after that night in Boston.
Adrian had done the math six months ago, sitting in his car, watching her buckle the boy into the back seat of a beat-up Honda Civic. He had told himself it was coincidence. He had told himself there were a thousand explanations. He had told himself that he was seeing patterns where none existed because his life had become small and paranoid and he needed something to blame for his failures.
He opened the file.
Nadia Ashford’s genetic profile was in there, captured via “residual DNA collected from water glass, Sterling Biotech lobby, 03/15/2020.” The memorandum noted that she had been in the building for a freelance photography gig. Someone had taken her glass after she left.
Adrian kept flipping. Box after box, file after file. He found consent forms that had been altered, signatures that appeared genuine but were dated after the procedures they authorized. He found records of children—dozens of them—whose genetic profiles had been uploaded to Project Chimera without their parents’ knowledge.
He found Toby’s file.
It was thin. A single page, typed, no letterhead, as if someone had printed it in a hurry and forgotten to add official markings.
*Subject: Ashford, Toby (minor)*
*Date of Birth: 08/12/2016*
*Genetic Anomaly: CRISPR-Cas9 integration detected, chromosome 4, locus 4q21.1. Alteration consistent with Project Chimera genotype A-7.*
Adrian’s vision narrowed. He blinked, hard, and re-read the line.
*CRISPR-Cas9 integration detected.*
He had been working on CRISPR-Cas9 gene editing during his postdoctoral fellowship. He had been developing methods to correct single-gene disorders. He had been Grant Sterling’s star pupil, the one who could code the repair sequences, the one who understood the mechanism better than anyone.
He had never considered that someone might use his work to edit a child’s genome without consent.
He checked the date on Toby’s file. The analysis had been run in June 2020, when Toby was three years old. Someone at Sterling Biotech had flagged the anomaly. Someone had filed this report. Someone had decided not to act on it.
Or someone had decided to wait.
Adrian’s phone vibrated against the metal desk. He ignored it. He was already pulling more boxes, checking more files, building a mental map of the deception. The clinical trials from 2019 to 2022. The consent forms that didn’t match the procedures. The genetic profiles of children whose parents had never authorized testing.
The pattern was clear. Grant Sterling had been running an illegal gene-editing trial on human subjects, using CRISPR-Cas9 to modify embryos for a trait he called “genotype A-7.” Adrian didn’t know what A-7 did—the notes were coded, deliberately opaque—but he knew it was in his son’s genome.
His phone vibrated again. He glanced at the screen. It was a text from an unknown number. No preview.
He ignored it and returned to the files. There was more. There had to be more. Somewhere in this room, there was a key that would unlock the full scope of the operation.
He opened box 512. It was empty except for a single photograph.
The photograph showed a laboratory. White walls, stainless steel countertops, equipment that Adrian recognized from his postdoctoral days. In the center of the image stood Grant Sterling, his silver hair impeccable, his white coat pristine. Beside him, a clipboard held a list of names.
Adrian squinted at the clipboard. The names were too small to read, but he could make out the header: *Project Chimera — Subject Roster — Cohort A-7.*
The photograph was dated February 2020. Toby was born in August 2016.
Adrian picked up his phone. The missed call was from a number he didn’t recognize. The text message read: *”You have accessed restricted files. Your badge has been logged. Sterling Tower, executive suite. Tonight. Come alone.”*
He stared at the message for a long moment. Then he saved the photograph, closed the boxes, and walked out of the archive room.
The executive suite was on the forty-second floor. Adrian had never been higher than the fourteenth. He took the elevator, watching the floor numbers climb, feeling the pressure change in his ears.
The doors opened onto a hallway of polished marble and soft lighting. A reception desk stood empty at the far end. Behind it, a door was ajar.
Adrian walked toward it. His footsteps made no sound on the marble.
He pushed the door open.
Grant Sterling sat behind a mahogany desk, his hands folded, his expression unreadable. Beside him, Jasper Sterling leaned against the window, silhouetted against the city lights.
“Adrian,” Grant said. “I was wondering when you would find it.”
“You edited my son’s genome without my consent.”
Grant did not flinch. “I edited your son’s genome before he was conceived. The modification was applied to the germline during the zygote stage. You were not the father at the time. You were not even aware that you had become one.”
Adrian’s hands curled into fists at his sides. “That’s not—”
“A legal defense?” Jasper interrupted, turning from the window. His face was smooth, handsome, utterly devoid of remorse. “It is a scientific one. The modification was necessary to ensure viability. Your son would not have survived birth without it.”
“You don’t know that.”
“We do,” Grant said. “We have the data. We have been tracking the outcomes of the A-7 cohort for eight years. The children are healthy. They are thriving. They are proof that genetic editing can be done safely, ethically, and without the knowledge of the parents who would have protested it.”
Adrian thought of Toby. Eight years old. Brown hair, brown eyes, a smile that lit up the car when his mother picked him up from school. A normal child, living a normal life, unaware that his genome had been rewritten before he was born.
“You can’t keep this secret forever,” Adrian said.
Grant smiled. It was a thin, unpleasant expression. “We don’t need to keep it forever. We only need to keep it until the clinical data is complete. Another twelve years. Then we publish, we change the world, and everyone forgets how we got there.”
“And if I don’t cooperate?”
Jasper laughed. It was a short, sharp sound. “You’ve been a data entry clerk for three years. You have no savings, no reputation, no credibility. You try to expose us, and we bury you in legal fees until you die. We might even let you see your son first. It would make the restraining order more painful.”
“I want to see the full Project Chimera files.”
“No,” Grant said. “You want to protect your son. Good. That’s the correct instinct. Here is what you will do: you will return to your basement. You will finish your cross-referencing. You will tell no one what you found. And in return, your son remains healthy, your ex-lover remains employed, and you remain breathing.”
Adrian held his gaze. The clock on the wall ticked. The city hummed below.
“Is that a threat?”
“It is a promise,” Grant said. “The Sterling family always keeps its promises.”
Adrian turned and walked out.
The elevator ride down was silent. The lobby was empty. The turnstile chirped as he passed through, and the cold night air hit his face as he stepped outside.
He stood on the sidewalk, looking up at the glass tower that held his son’s genetic secrets, and thought about what he had learned. He thought about Grant’s confidence. Jasper’s cruelty. The photograph in the box, the clipboard with the names.
He thought about Toby’s smile.
Then he started walking. He did not know where he was going. He only knew that he had to move, to think, to find a way out of the trap that had been closing around him since before his son was born.
At the corner, he stopped. A figure was standing in the shadows beside a parked car. A woman, slim, dark-haired, her hands shoved into the pockets of a worn leather jacket.
Nadia Ashford.
She was watching him. Her face was pale, her eyes wide. She looked like she had been running.
“Nadia,” he said.
She shook her head. “Don’t. Don’t say my name. Don’t pretend you know me.”
“I know about Toby.”
Her expression crumbled, then hardened. “You don’t know anything. You don’t know what I’ve done to keep him safe. You don’t know what they’ve threatened.”
“Tell me.”
Nadia’s phone buzzes with a text from an unknown number: ‘Your son’s DNA has been flagged. Attend the Sterling Manor gala tomorrow, alone, or the trial begins without you.’